TCM
JBIO icon

Tang Capital Management’s Jade Biosciences JBIO Stock Holding History

Tang Capital Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,993
Closed -$175K – 204
2025
Q1 		$175K Buy
+1,993
New +$175K 0.01% 198

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tang Capital Management's JBIO Position: Q2 2025 in Review

Tang Capital Management sold out of Jade Biosciences (JBIO) in Q2 2025, closing a stake of 1,993 shares — an estimated $175K sold.

Tang Capital Management first reported a position in JBIO in Q1 2025 and held it in 1 quarter. The position peaked at $175K in Q1 2025. 75 funds tracked by Wall St. Rank hold JBIO as of Q2 2025.

  • Tang Capital Management reported no remaining Jade Biosciences position as of Q2 2025 after selling out during the quarter.
  • Tang Capital Management sold 1,993 Jade Biosciences shares in Q2 2025, an estimated $175K.
  • Tang Capital Management first reported a position in Jade Biosciences in Q1 2025 and held it in 1 quarter.
  • Tang Capital Management's Jade Biosciences position peaked at $175K in Q1 2025.
  • 75 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2025.

Based on Tang Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.